Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q9BY44
UPID:
EIF2A_HUMAN
Alternative names:
65 kDa eukaryotic translation initiation factor 2A
Alternative UPACC:
Q9BY44; A8MPS6; B4DF96; B4DQ14; D3DNI9; Q5QTR2; Q7Z4E9; Q8NFM1; Q96EW9; Q96K81
Background:
Eukaryotic translation initiation factor 2A, a 65 kDa protein, plays a pivotal role in the early steps of protein synthesis. It uniquely directs the binding of methionyl-tRNAi to 40S ribosomal subunits in a codon-dependent manner, distinguishing itself from the eIF-2 complex's GTP-dependent binding method.
Therapeutic significance:
Understanding the role of Eukaryotic translation initiation factor 2A could open doors to potential therapeutic strategies.